We found that the GM-CSF expression was induced significantly in both groups; however, no significant differences in GM-CSF expressing Th17 cells (phenotyped as CD3+ CD8- IL-17+ GM-CSF+ cells) between MS patients and controls were observed (p = 0.94) (Figure 1C). This evidence concerns the gene CSF2 and myeloid sarcoma.